Deutsch
English
Русский

Universitätsklinikum Würzburg 

ZIM (Zentrum Innere Medizin)
Haus A3/A4 

Oberdürrbacherstr. 6

97080 Würzburg

ZOM / ZIM

Studien - Pilzinfektionen

Inf-Wü002: Evaluation of non-culture based tests, using bronchoalveolar lavage in triplicate testing and serum, to establish diagnosis of a pulmonary aspergillus disease.

Non AMG IIT

Sponsor: University Hospital Wuerzburg

Time period: 11/2013 – ongoing

Role: LKP/PI

 

MSD/Merck No. MK-5592-069: A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults

EudraCT No.: 2011-003938-14

ClinicalTrials.gov Identifier: NCT01782131

http://www.clinicaltrials.gov/ct2/show/NCT01782131?term=NCT01782131&rank=1

Sponsor: MSD/Merck

Phase: III

Time period: 11/2013 – ongoing

Role: PI

 

EORTC - 65091-06093: Empirical versus pre-emptive antifungal therapy of patients with haematological malignancies. A therapeutic open label phase III strategy study of the EORTC Infectious diseases and leukemia Groups.

EudraCT No. : 2010-020814-27

ClinicalTrials.gov Identifier: NCT01288378; http://www.clinicaltrials.gov/ct2/show/NCT01782131?term=NCT01782131&rank=1

Sponsor: European Organisation for Research  and Treatment of Cancer (EORTC)

Phase: III

Time period: 11/2012 – ongoing

Role: PI

 

A phase III, randomised, observer-blind, placebo controlled, multicentre, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals’ herpes zoster gE/AS01B vaccine when administered intramuscularly on a two dose schedule to adult autologous haematopoietic stem cell transplant (HCT) recipients.

EudraCT No.: 2012-000138-20

ClinicalTrials.gov Identifier: NCT01610414

http://www.clinicaltrials.gov/ct2/show/NCT01610414?term=NCT01610414&rank=1

Sponsor: GlaxoSmithKline

Phase III

Time period: seit 9/2012 - ongoing

Role: LKP

 

A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs),

EudraCT No.: 2010-020150-34

ClinicalTrials.gov Identifier: NCT01229267

http://clinicaltrials.gov/ct2/show/NCT01229267?term=NCT01229267&rank=1

Sponsor: Merck Sharp & Dohme Corp.

Phase III

Time period: 5/2011 - ongoing

Role: PI